Securities code: Fujian Cosunter Pharmaceutical Co.Ltd(300436) securities abbreviation: Fujian Cosunter Pharmaceutical Co.Ltd(300436) Announcement No.: 2022042 Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Announcement on special explanation of profit distribution plan in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
According to the 2021 annual audit report of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as the “company”) issued by Dahua Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the listed company in the consolidated statements of the company in 2021 was -3488655027 yuan, and the net profit of the parent company in 2021 was -5066624529 yuan. As of December 31, 2021, the profit available for distribution in the consolidated statements of the company is 18089018064 yuan, the capital reserve is 65929404369 yuan and the surplus reserve is 4439383331 yuan; The profit available for distribution in the statement of the parent company is 15328824485 yuan, the capital reserve is 66373224479 yuan and the surplus reserve is 4439383331 yuan.
1、 2021 profit distribution plan
In accordance with the provisions of the articles of association and in combination with the company’s future development needs, operation and cash flow, the company plans not to distribute cash dividends, bonus shares or transfer capital reserve into share capital in 2021, and the undistributed profits will be retained by the company to support the company’s operation and development.
The plan has been deliberated and approved at the 13th meeting of the 4th board of directors and the 12th meeting of the 4th board of supervisors, and needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
2、 Reasons for no profit distribution in 2021
In 2022, the company continued to scale up and innovate. Anti New Coronavirus small molecule oral innovation GST-HG171 is currently in pre clinical research phase. The company is integrating resources to fully promote the research and development of the project. Up to now, the company’s hepatitis B treatment innovative medicine GST-HG141 has completed Ib phase, is preparing for phase II clinical trials, and is a new c-Met tumor targeting drug GST-HG161 is carrying out the phase Ib clinical trial, hepatitis B surface antigen inhibitor GST-HG131 Ia phase clinical trial. The drug has been completed by all subjects, and tolerance, safety observation, non-alcoholic steatohepatitis and liver fibrosis treatment of new drug GST-HG151 the first case has successfully been enrolled. Hepatitis B treatment Innovation Medicine GST-HG121 is actively promoting the preparation of I phase clinical trial. In 2022, with the in-depth promotion of the R & D of the above six innovative drugs, it is expected that there will be a large demand for funds in 2022. Therefore, in order to ensure the demand for follow-up operation and R & D funds, reduce financial costs, accelerate the implementation of innovation and development strategy, and create greater medium and long-term benefits for shareholders, the company plans not to distribute cash dividends, bonus shares or increase share capital with capital reserve in 2021.
3、 Purpose and use plan of undistributed profits of the company
The retained undistributed profit will be used for companies to continue to develop their businesses and promote the implementation of innovative development strategies, including, but not limited to, anti small molecule oral innovative drugs GST-HG171, new c-Met tumor targeting drugs GST-HG161, non-alcoholic steatohepatitis and new liver fibrosis treatment GST-HG151, hepatitis B treatment of innovative drugs such as GST-HG141, GST-HG131, GST-HG121 clinical trials of innovative drugs such as c-Met. 4、 Opinions of independent directors
The board of directors of the company comprehensively considered the company’s future development strategy and capital arrangement, and put forward a plan for no profit distribution in 2021. The plan is in line with the long-term development needs of the company and the interests of all shareholders of the company. There is no damage to the interests of investors. Its decision-making procedures comply with relevant laws and regulations and the articles of association. We unanimously agree to the plan and agree to submit it to the general meeting of shareholders for deliberation.
It is hereby announced.
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of directors April 21, 2022
